Prosecution Insights
Last updated: October 25, 2026
Application No. 18/855,329

USE OF PRUNUS LANNESIANA EXTRACT FOR IMPROVING SKIN CONDITION AND BASAL METABOLIC RATE

Non-Final OA §102§112
Filed
Oct 09, 2024
Priority
Jul 08, 2022 — provisional 63/359,204 +1 more
Examiner
CHEN, CATHERYNE
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
TCI Co., Ltd.
OA Round
1 (Non-Final)
38%
Grant Probability
At Risk
1-2
OA Rounds
2y 2m
Est. Remaining
55%
With Interview

Examiner Intelligence

Grants only 38% of cases
38%
Career Allowance Rate
297 granted / 793 resolved
-22.5% vs TC avg
Strong +18% interview lift
Without
With
+17.9%
Interview Lift
resolved cases with interview
Typical timeline
4y 3m
Avg Prosecution
56 currently pending
Career history
849
Total Applications
across all art units

Statute-Specific Performance

§101
14.5%
-25.5% vs TC avg
§103
41.2%
+1.2% vs TC avg
§102
18.3%
-21.7% vs TC avg
§112
19.6%
-20.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 793 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 1-11 are pending. Claims 1, 6, and 7 are examined on the merits. Claims 2-5 and 8-11 are withdrawn. Election/Restrictions Claims 2-4 and 8-11 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected species, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 9/10/2026. Applicant's election with traverse of Claim 6 in the reply filed on 9/10/2026 is acknowledged. The traversal is on the ground(s) that “improving a skin condition” would include “skin roughness, stability of skin condition, skin tightness, skin sallowness, skin glossiness and brightness, skin tenderness and smoothness, skin sensitivity or skin moisture”. This is not found persuasive because a search of one group is not coextensive with the search of the other groups. A method of treating one skin condition does not result in other skin conditions being treated. Thus, it would be burdensome to search the entire claims. The requirement is still deemed proper and is therefore made FINAL. Information Disclosure Statement The information disclosure statements (IDS) submitted on 8/20/2026, 1/22/2026, 10/18/2024 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 6, and 7 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 1 and 7 contain the term “(20-40):1”. Why is the weight ratio in parentheses? It is part of the claim? Please correct. Claims 1, 6, and 7 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being incomplete for omitting essential steps, such omission amounting to a gap between the steps. See MPEP § 2172.01. The omitted steps are: administering. How is the composition administered for improving a skin condition? Please elaborate. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1, 6 and 7 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Tan et al. (CN 114376950 A). Tan et al. teaches the use of plant raw material: rosemary leaf, tap bamboo leaf, Japanese cherry blossom, hemp leaf, grinding into fine powder by 60-mesh sieve, filter the mesh fine crushing part of plant raw material, the respectively plant raw material powder uniformly mixing; (2) according to the ratio of the material liquid extracted by the ethanol determined by the orthogonal experiment: 1: 35, weighing proper pure ethanol reagent for soaking the plant raw material powder for 1 hours, placing the electric heating sleeve for heating, heating the temperature to 78 degrees centigrade, opening the cold circulating water for hot reflux extraction for 2 hours (Example 1) in a cosmetic composition. The cosmetic composition takes the natural extract as active ingredient, it has high anti-inflammatory activity, the effect of removing dead skin cells of the skin is moderate, it can effectively improve the glossiness of the skin, reduce the roughness of the skin, make the skin better absorb nutrition, and the irritation of the skin is small, skin has no side effect, has good effect of cleaning dead skin cells, safety, green natural for all skin of people (Abstract). Japanese cherry blossom is also known as Prunus lannesiana flower (Specific implementation examples). Conclusion No claim is allowed. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to CATHERYNE CHEN whose telephone number is (571)272-9947. The examiner can normally be reached on Monday-Friday 9-5:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice . If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand U Desai can be reached on 571-272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Catheryne Chen Examiner Art Unit 1655 /ANAND U DESAI/Supervisory Patent Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Oct 09, 2024
Application Filed
Oct 02, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12766179
Oral Formulations Containing Enriched Polyphenolic Compounds together with a Form of Creatine, a Source of Choline and Trisodium Citrate
5y 5m to grant Granted Oct 20, 2026
Patent 12741000
TRADITIONAL CHINESE MEDICINE COMPOSITION FOR TREATING PSORIASIS, PREPARATION METHOD THEREFOR AND USE THEREOF
4y 4m to grant Granted Sep 22, 2026
Patent 12697564
Dephosphorylation-controlled extraction of phosphorylatable psychoactive alkaloids
2y 10m to grant Granted Aug 04, 2026
Patent 12673114
COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING IL-2 SURFACE EXPRESSION-EXTRACELLULAR VESICLES AS ACTIVE INGREDIENT
4y 6m to grant Granted Jul 07, 2026
Patent 12622869
LIPID EMULSION FOR PARENTERAL ADMINISTRATION
5y 4m to grant Granted May 12, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
38%
Grant Probability
55%
With Interview (+17.9%)
4y 3m (~2y 2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 793 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month